The latest Investing Matters Podcast episode featuring financial educator and author Jared Dillian has been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
And this is just the beginning
RBC capital target 60p
9.575-9.999p
This is clearly going places big appointment there heavyweight
Jonboi1968 speaks the truth
At break even now and this is still under the radar. Multi-bagger in the making.
Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) has appointed Joseph P. ("JP") Errico as Chief Financial Officer.[i] JP will be responsible for managing and developing Ondine's finance function, as well as managing the capital markets interface, participating in discussions with large health systems and customers, and working closely with the management team on overall growth strategy, both from a financial and operational perspective.
JP has successfully founded and sold (or taken public) several medical device and pharmaceutical companies, including ElectroCore, Fastenetix, K2 Medical Systems, AD4-Pharma, E2, and SpineCore, with his patented products generating over $20 billion in sales.
Carolyn Cross, CEO and founder of Ondine commented:
"We are delighted that JP has agreed to join Ondine at this exciting time. His experience in finance, capital markets and developing medtech companies will be invaluable as we move forward with our international expansion and achieving FDA approval in conjunction with our partner HCA Healthcare."
JP Errico commented:
"Ondine represents a unique opportunity to create shareholder value while heading off one of humanity's greatest health threats, antimicrobial resistance. I am proud to be joining an excellent team of professionals as Ondine brings this critically needed technology to the world."
JP's educational background includes an undergraduate degree in Aeronautical Engineering from the Massachusetts Institute of Technology and graduate degrees in both Law and Mechanical/Materials Engineering from Duke University. He is also a trained patent attorney.
9.10-9.49p
Starting to make its move
Ondine Biomedical Inc - Vancouver-based life sciences company - Appoints Joseph Errico as chief financial officer, though doesn't provide start date. Says Errico has successfully founded, sold, or taken public several medical device and pharmaceutical companies, including ElectroCore, Fastenetix, K2 Medical Systems, AD4-Pharma, E2, and SpineCore.
Chief Executive Officer Carolyn Cross says: "We are delighted that JP has agreed to join Ondine at this exciting time. His experience in finance, capital markets and developing medtech companies will be invaluable as we move forward with our international expansion and achieving FDA approval in conjunction with our partner HCA Healthcare."
You guys really get behind your investments
Cross said the fact that many hospitals were recommending Steriwave to other hospitals was "particularly encouraging".
"We believe this momentum will continue to increase, and commercial sales will become more significant in 2024."
Efforts to be a commercial success
currently achieving break-even or better
in my view but do you own research
Mark my words
dyor - imo
Thinking of investing here what we all saying like what i hear merry xmas guys
Chief Executive Officer Carolyn Cross commented: "It is hugely satisfying that Steriwave is now available in hospitals from coast to coast across Canada, giving patients enhanced protection against post-surgical infections. This new hospital deployment demonstrates Steriwave's growing status as an effective alternative to topical antibiotics for infection prevention that easily fits into existing hospital workflows."
More buys than sells still down on the day =rigged market
Light fuse and stand well back - because this is taking off in 2024
and the sky is the only limitation
RBC target is 60p (will outperform the market)
imho dyo
Hope they have full patents on their technology. This one still under the radar but for how long ? Millions of machines would be required Worldwide when this disinfectant process fully takes off. OBI would make a fortune if they could just get a small % of this market potential. Light fuse and stand well back, it`s coming home....
Chief Executive Carolyn Cross says: "We have put great efforts into improving our commercial activity sales process, which has increased the speed of the average sales cycle from contact to deployment by 50%. We have appointed distributors in the UK, Spain, and Mexico and are gaining real momentum. What is particularly encouraging is that many hospitals are recommending Steriwave to other hospitals. We believe this momentum will continue to increase, and commercial sales will become more significant in 2024."
Am in total agreement with Rocket
Can see Steriwave being used as the standard practice and replace antibiotics due to high resistance. The infection rates of hospital infections after surgery in U.K. has a massive cost in aftercare and taking beds up for longer periods. This one could be a multi-bagger very soon IMO.
Ondine met its 2023 target and more than doubled the number of hospitals using its groundbreaking photodisinfection technology to reduce healthcare-associated infections (HAIs)
· According to the NIH, HAIs affect more than 2 million patients a year in the US, leading to over 90,000 deaths and incurring costs exceeding $30 billion a year.[1]
Following its successful fundraising of C$4.91 million (US$3.62), Canadian life sciences company Ondine Biomedical Inc. (AIM: OBI) will continue accelerating commercialisation of its proven nasal photodisinfection technology. This cutting-edge technology replaces topical antibiotics for the prevention of healthcare-associated infections (HAIs) and kills all types of pathogens - bacteria, viruses and fungi - without causing antimicrobial resistance.
The Company has confirmed that it has more than doubled the number of Steriwave® deployments in 2023 and is in discussions with more than 75 hospitals in the UK, Mexico, Spain, and Canada. The growing global emphasis on preventing HAIs post-surgery, coupled with the escalating challenge of antimicrobial resistance, has spurred heightened interest in Ondine's photodisinfection technology.
The deployments are in areas of major surgery, including spinal, orthopedic, and cardiovascular. The antibiotic mupirocin has been used for nasal decolonization for the prevention of HAIs since the 1980s. However, mupirocin has resistance rates of up to 81%,[2] and very poor compliance.[3]
Successful C$4.91 raise supports ongoing commercialisation
Pentwater employs a bottom-up, opportunistic investment approach with a focus on event driven investing across the capital structure. Active risk management and capital preservation are key priorities. The seasoned Pentwater team enjoys a collaborative culture across the firm’s offices and strategies. In addition to our investment process, we are committed to providing investors with institutional quality client service, operations, and compliance.
Notification of major holdings